BTC 
ETH 
BNB 
XRP 
SOL 
TRX Regeneron, Sanofi rise as Dupixent beats Q3 sales forecasts
Investor's Business Daily reported that Regeneron stock rose Thursday after its Sanofi-partnered drug Dupixent easily beat third-quarter sales expectations. The post attributes the surge to Dupixent's outperformance versus forecasts.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Regeneron stock rose Thursday after Dupixent beat third-quarter sales forecasts.
“Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat third-quarter calls.”
Investor's Business Daily
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-30 13:00 UTC. Labels are computed from the sources, not by the model.